CAR-T reimbursement: Lessons learnt from NICE assessments

By Max Rex, Analyst Email: It’s been difficult to keep up with the flurry of reimbursement news coming out of England relating to the recently approved CAR-T therapies Kymriah (Novartis) and Yescarta (Gilead). Despite only having gained EMA (European Medicines Agency) approval in late August this year, England’s medicines watchdog, NICE (National Institute of […]

Read More


NICE balks at Spinraza price, rejects reimbursement in its draft guidance

By Christina Poschen, Consultant Email: Biogen’s Spinraza, a treatment for the rare genetic disease spinal muscular atrophy (SMA) is currently making headlines for its high price and promising outcomes.  Various European countries including Spain, Italy as well as The Netherlands and Belgium just made the product available to their patients or confirmed they will […]

Read More


Seven months to Brexit, does the biopharma industry have the tools to be ready?

Everything you need to know about the latest Brexit White Paper By Joanna Fernandes, Analyst Email: As the countdown to Brexit draws near, a flurry of activities has emerged from the UK government, the EU and the pharma/biotech industry. But central to the conversation is the recent white paper released by the UK government […]

Read More


Slow Brexit proceedings frustrates biotech industry

By Aparna Krishnan, Corporate Affairs Lead As the UK Prime Minister’s office is preparing for the cabinet meeting at Chequers this Friday, British businesses including the biotech industry are none the wiser on what lays ahead after March 29, 2019 when the UK exits the European Union. The current discussion is focussed on the Brexit […]

Read More


Faster route to access in Scotland for rare disease patients requiring ultra-orphan drugs

By Alison Kneen, Vice President International Operations Fantastic news for Scottish patients who suffer from very rare diseases. As of October 1, 2018, patients will receive faster access to new treatments as a result of changes being made to the Scottish Medicine Consortium (SMC), the health technology assessment (HTA) body pathway which is used to evaluate […]

Read More


Cancer diagnosis – a step forward for England

New rapid diagnostic and assessment centres are being piloted in ten areas across England in a focused approach to identify cancer early.  These new centres are part of the NHS plan to meet the new faster diagnosis standard, where patients with suspected cancer should receive a diagnosis or given the all clear within 28-days. The […]

Read More


PRIME – two-year assessment – was it good for biopharma?

The PRIority Medicines Scheme (PRIME) of the European Medicines Agency (EMA) was started two years ago to support and optimise medicine development. The scheme provides early and enhanced scientific and regulatory support to medicines that have the potential to significantly address patients’ unmet medical needs. The EMA has published their two-year review and not surprisingly more than […]

Read More


Irish patients continue to be denied vital new drugs

Todays’ article in the Irish Times[1] highlights again that patients in Ireland continue to be denied nine drugs which are already approved for use by the National Centre of Pharmacoeconomics (NCPE). They have been waiting on average for 2 years for the Health Service Executive (HSE) to approve them for reimbursement. The drugs concerned range […]

Read More


CDF to save NHS £140m over five years

The Cancer Drugs Fund (CDF) is expected to save the U.K. National Health Service (NHS) a minimum of £140 million over the next five years. Medicines that are recommended to the CDF by NICE (National Institute of Health and Care Excellence) have their prices negotiated lower than the manufacturer’s initial listed price. Over 15,000 patients […]

Read More


Cancer treatments: A brief history

February 4 was World Cancer Day and here at Partners4Access, we are having a look back at how cancer treatments have evolved through the years and where they are likely to go in the future. First came surgery In the 18th century, surgery was hailed as the first effective cancer treatment. The discovery of anesthesia […]

Read More

All Rights Reserved ©   Privacy   Partners 4 Access 2018